Biomarker study of folate receptor alpha(FOLRa)using paired samples of breast cancer tissue

Biomarker study of folate receptor alpha(FOLRa)using paired samples of breast cancer tissue - PairFOLRa

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050787

Enrollment

100

Registered

2023-04-09

Start date

2021-06-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age 20 years or older 2. Pathologically confirmed as triple-negative breast cancer or ER-positive, HER2-negative breast cancer 3. Have undergone tumor collection at two or more different timings, and able to submit tissue samples

Exclusion criteria

Exclusion criteria: 1.Not undergoing systemic therapy 2.Patients deemed unsuitable by a physician for other reasons

Design outcomes

Primary

Measure	Time frame
Proportion of the patients with FOLRa-positive breast cancer	—

Secondary

Measure	Time frame
Proportions of cases with increased, unchanged, or decreased IHC scores for FOLRa in paired samples (primary vs. metastatic, pre- vs. post-treatment) Correlation of FOLRa scores in cell membrane, cytoplasm, and cell membrane + cytoplasm Association between FOLRa expression and ER/PgR positivity, Ki-67 index, and PD-L1 positivity Relationship between treatment regimen and changes in FOLRa expression levels	—

Measure

Time frame

Proportions of cases with increased, unchanged, or decreased IHC scores for FOLRa in paired samples (primary vs. metastatic, pre- vs. post-treatment) Correlation of FOLRa scores in cell membrane, cytoplasm, and cell membrane + cytoplasm Association between FOLRa expression and ER/PgR positivity, Ki-67 index, and PD-L1 positivity Relationship between treatment regimen and changes in FOLRa expression levels

—

Countries

Japan

Contacts

Public ContactHitomi Sakai

Showa University Advanced Cancer Translational Research Institute

sakai-h@med.showa-u.ac.jp03-3784-8146

Outcome results